The Development of Combination Therapies to Treat Viral Diseases is Key to Future Treatment and the Focus of Recent Pharma Collaborations

The Development of Combination Therapies to Treat Viral Diseases is Key to Future Treatment and the Focus of Recent Pharma Collaborations

Lisa Osgood, 781-993-2606orChristopher Comfort, 781-993-2597

Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the development of combination therapies for hepatitis c virus (HCV) and fixed-dose combinations and single-tablet regimens for human immunodeficiency virus (HIV) is key to future therapy for these diseases. According to , several recent pharmaceutical company deals include collaborations in which different companies contribute drugs to the development or testing of a potential combination regimen.

Among these relationships is the 2011 clinical collaboration between Bristol-Myers Squibb and Janssen (formerly Tibotec Pharmaceuticals) to evaluate a combination of Bristol-Myers Squibb’s NS5A inhibitor daclatasvir (BMS-790052) and Tibotec’s NS3/4A protease inhibitor TMC-435 (licensed from Medivir) for the treatment of HCV. In 2012, the partners expanded the agreement to include a Phase III trial and a drug-drug interaction study of TMC-435 and the NS5B inhibitor BMS-986094.

“Investigational combinations for HCV, including novel agents targeting the HCV NS3/4A protease, NS5A protein and/or NS5B polymerase, will move HCV treatment closer to the all-oral regimen eagerly sought by patients and physicians to replace injectable peg-IFN and ribavirin, and promise to improve response rates and tolerability,” said Decision Resources Principal Analyst Barbara Bolten, M.S., M.B.A. “For HIV, fixed-dose combinations and single-tablet regimens will address the need to simplify antiretroviral therapy for long-term use in HIV patients. For both the HCV and HIV markets, these combination therapies present significant commercial opportunity.”

Decision Resources’ forecasts that the total worldwide antivirals market, which includes sales of hepatitis treatments, HIV treatments and other antivirals, will grow from approximately $22 billion in 2007 to nearly $37 billion in 2018.

is a new report from Decision Resources. This report covers multiple viral diseases, including HIV, HCV, influenza virus, herpes virus, human papilloma virus, respiratory syncytial viruses and others. Through , pharmaceutical business development and strategic planning teams can understand where key opportunities lie. Each report features a clinical development pipeline (Phase I-III) of novel drugs, a pipeline analysis and an overview of development programs by drug target or mechanism of action. Reports identify and highlight innovator companies that offer discovery, preclinical and clinical partnering opportunities. In addition, an analysis of recent corporate deals highlights current partnering and dealmaking strategies.

Decision Resources () is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at .

Suggested Articles

Passage Bio filed to raise $125 million in its IPO. Now, it has outraised that goal by $91 million with a $216 million Wall Street debut.

The ruling reflects the judge’s belief that the FDA’s interpretation of the law on clinical trial reporting “is unlawful and must be set aside.”

Trutino will apply a platform designed to yield safer, more effective cytokines to the discovery of three oncology drugs for Boehringer.